ARID1A and endometrial carcinoma: Epistasis experiments show that both the hyperacetylation of select SEs and the greater invasive phenotype in endometrial carcinoma observed upon ARID1A deletion is attenuated with either genetic or pharmacologic inhibition of P300, suggesting it is required in the setting of ARID1A loss [25].